ArticleFrontiers in medicine2025
Global, regional, and national burden of multiple myeloma, 1990 to 2021 and predictions to 2035: an analysis of the Global Burden of Disease Study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Multiple myeloma (MM) is the second most common haematologic malignancy. This study aimed to assess the global burden of multiple myeloma across 204 countries and territories from 1990 to 2021. Methods: The data for this study were obtained from the Global Burden of Disease (GBD) 2021 dataset, which provides comprehensive information on the global and regional burden of 369 diseases, injuries, and 88 risk factors across 204 countries and territories from 1990 to 2021. We analyzed the incidence, mortality, disability-adjusted life years (DALYs), and disease-related risk factors of MM from 1990 to 2021. Age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) were calculated and analyzed. We also analyzed trends over time by gender and age, and assessed the impact of socio-demographic index (SDI) on disease burden. In addition, the global burden of MM from 2021 to 2035 was predicted by a Bayesian age-period-cohort (BAPC) model. Results: In 2021, there were 148,755 cases of MM globally. From 1990 to 2021, the global ASIR, ASMR, and ASDR increased (EAPC = 0.48, 0.09 and 0.06, respectively). In general, the ASIR, ASMR, and ASDR of MM and SDI levels are positive correlated, as regions with higher SDI levels normally have higher ASIR, ASMR, and ASDR. The incidence and mortality rates were higher in males than in females in all age groups, and increased with age before 90 years. We projected that the ASIR, ASMR, and ASDR of MM would obviously increase over the next dozen years through BAPC model. Conclusion: The findings in this study offer valuable insights into the global distribution and magnitude of the MM burden, which may be instructive for better making public health policy and reasonably allocating medical source.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.